Gsk Pharma

Motilal Oswal recommended Neutral rating on GSK Pharma with a target price of Rs 3000 in its research report dated August 02, 2025.

Q4 result impact: Dalmia Bharat Sugar shares up 9% as PAT more than doubles, GSK Pharma and AB Capital shares rise 5%

Q4 result impact | GSK Pharma reported a 35% rise in net profit to Rs 263 crore in Q4 FY25, while Aditya Birla Capital reported a net profit of Rs 864.60 crore for the fourth quarter, lower by nearly 31 percent on year.

GSK Pharma shares jump 15%, extend gains to 2nd straight day after strong Q3 results

GSK Pharma had reported a consolidated net profit of Rs 230 crore for Q3 FY25. This marks a significant surge of nearly 400 percent from the Rs 46 crore net profit reported in Q3 of previous financial year.

Neutral GSK Pharma; target of Rs 2620: Motilal Oswal

Motilal Oswal recommended Neutral rating on GSK Pharma with a target price of Rs 2620 in its research report dated August 05, 2024.

GSK Pharma shares sink 8% as Q3 net profit tanks

The pharma company's net profit declined 72 percent on year to Rs 46 crore. The bottomline also included exceptional expenses worth Rs 220 crore

GSK Pharma reports higher-than-expected profit in Q2; shares may rise

GSK Pharma reported better than expected PAT on lower raw material cost and increased benefit from marketing activities, along with high demand for vaccines.

Neutral GSK Pharma; target of Rs 1310: Motilal Oswal

Motilal Oswal recommended Neutral rating on GSK Pharma with a target price of Rs 1310 in its research report dated July 26, 2023.

Neutral GSK Pharma; target of Rs 1220: Motilal Oswal

Motilal Oswal recommended Neutral rating on GSK Pharma with a target price of Rs 1220 in its research report dated May 17, 2023.

Neutral GSK Pharma; target of Rs 1340: Motilal Oswal

Motilal Oswal recommended Neutral rating on GSK Pharma with a target price of Rs 1340 in its research report dated February 07, 2023.

Neutral GSK Pharma; target of Rs 1420: Motilal Oswal

Motilal Oswal recommended Neutral rating on GSK Pharma with a target price of Rs 1420 in its research report dated November 12, 2022.

Neutral GSK Pharma; target of Rs 1580: Motilal Oswal

Motilal Oswal recommended Neutral rating on GSK Pharma with a target price of Rs 1580 in its research report dated July 26, 2022.

Neutral GSK Pharma; target of Rs 1570: Motilal Oswal

Motilal Oswal recommended Neutral rating on GSK Pharma with a target price of Rs 1570 in its research report dated May 16, 2022.

GSK Pharma Q3 net profit jumps over two-folds to Rs 204 crore

The company had reported a net profit of Rs 76.47 crore in the same period of the previous fiscal.

Neutral GSK Pharma; target of Rs 1355: Motilal Oswal

Motilal Oswal recommended Neutral rating on GSK Pharma with a target price of Rs 1355 in its research report dated July 29, 2020.

GSK Pharma share price tanks 10% to hit 3-month low after Q3 loss of Rs 661 crore

The results were impacted due to voluntary global recall of ranitidine products, including Zinetac, said GlaxoSmithKline Pharmaceuticals Managing Director A Vaidheesh.

Rising stars? 14 stocks reported over 100% surge in PAT

Experts feel there are only a handful of companies that could be considered for investment for the year 2020

Glaxo Pharma falls over 3% as brokerages maintain bearish stance on weak margin, rich valuations

Citi, which also maintained its sell rating with a target price of Rs 1,340 (implying potential downside of 2 percent), said the business is clearly recovering, but it does not see margins back at 30 percent range.

Buy GSK Pharma ; target of Rs 3100: Dolat Capital

Dolat Capital is bullish on GSK Pharma has recommended buy rating on the stock with a target price of Rs 3100 in its research report dated February 02, 2017.

Should a high price deter you from owning a company's shares?

Some investors shy away from buying stocks that have high prices. The belief is unfounded.

Sensex, Nifty maintain uptrend; Aurobindo, GSK rally

Aurobindo Pharma gained 3.7 percent after the company's US subsidiary emerged as highest bidder to acquire Natrol with bid of USD 132.5 million.

Dose of bitter pills, booster injections for pharma sector

The Indian pharma sector, estimated to be around Rs 1.5 lakh crore, recorded single digit growth for the first time in several years on account of deeper price cuts under pricing policy and selective boycott of companies by the retailers.

Stocks in news: Axis, Infosys, United Spirits, UB Holdings

GAIL | GSK Pharma | Axis Bank | Wipro | ICICI Bank | Larsen and Toubro | IOC | Infosys | Financial Technologies | United Spirits and United Breweries Holdings are stocks, which are in the news today.

Bullish on Lupin, Aurobindo; cautious on Ranbaxy: Religare

Arvind Bothra, vice president of institutional research at Religare Capital Markets is cautious on Ranbaxy because the earnings visibility is very low and believes that the expectations of a turnaround in the US business etc are seemingly priced-in the stock.

GSK Pharma a long term bet: Experts

But Daljit Singh Kohli, IndiaNivesh Securities advises investors to tender in the offer and get out.